Registre de correu electrònic: Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)” study: A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome